BR112014017217A2 - agente e composição farmacêutica - Google Patents

agente e composição farmacêutica

Info

Publication number
BR112014017217A2
BR112014017217A2 BR112014017217A BR112014017217A BR112014017217A2 BR 112014017217 A2 BR112014017217 A2 BR 112014017217A2 BR 112014017217 A BR112014017217 A BR 112014017217A BR 112014017217 A BR112014017217 A BR 112014017217A BR 112014017217 A2 BR112014017217 A2 BR 112014017217A2
Authority
BR
Brazil
Prior art keywords
composition
pharmaceutical agent
pharmaceutical
agent
Prior art date
Application number
BR112014017217A
Other languages
English (en)
Other versions
BR112014017217A8 (pt
BR112014017217B1 (pt
Inventor
Reyes Moreno Blanca
Amat Riera Isabel
Mercè Amat Fabregat Maria
Joan Cardona Iglesias Pere
Original Assignee
Archivel Farma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archivel Farma Sl filed Critical Archivel Farma Sl
Publication of BR112014017217A2 publication Critical patent/BR112014017217A2/pt
Publication of BR112014017217A8 publication Critical patent/BR112014017217A8/pt
Publication of BR112014017217B1 publication Critical patent/BR112014017217B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/001Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112014017217-0A 2012-01-12 2012-01-12 Agente e composição farmacêutica BR112014017217B1 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2012/000353 WO2013104943A1 (en) 2012-01-12 2012-01-12 Mtb-c vaccine against asthma

Publications (3)

Publication Number Publication Date
BR112014017217A2 true BR112014017217A2 (pt) 2017-06-13
BR112014017217A8 BR112014017217A8 (pt) 2017-07-04
BR112014017217B1 BR112014017217B1 (pt) 2023-01-17

Family

ID=45852617

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014017217-0A BR112014017217B1 (pt) 2012-01-12 2012-01-12 Agente e composição farmacêutica

Country Status (15)

Country Link
US (1) US9682042B2 (pt)
EP (1) EP2802345B1 (pt)
CN (1) CN104411326B (pt)
AU (1) AU2012365465B2 (pt)
BR (1) BR112014017217B1 (pt)
CA (1) CA2861074C (pt)
DK (1) DK2802345T3 (pt)
ES (1) ES2670493T3 (pt)
IN (1) IN2014MN01594A (pt)
NO (1) NO2802345T3 (pt)
PL (1) PL2802345T3 (pt)
PT (1) PT2802345T (pt)
RU (1) RU2602771C2 (pt)
WO (1) WO2013104943A1 (pt)
ZA (1) ZA201405107B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103720657B (zh) * 2013-11-19 2017-01-04 广东丸美生物技术股份有限公司 一种可变形脂质体的制备方法,及其制备的可变性脂质体
RU2652752C1 (ru) * 2017-06-15 2018-04-28 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии" Способ лечения бронхиальной астмы
EP3797791A1 (en) * 2019-09-26 2021-03-31 Universidad De Zaragoza Therapeutic efficacy by pulmonary delivery of live attenuated mycobacteria

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9900378A3 (en) 1995-02-22 1999-11-29 Adcock Ingram Ltd A method for the isolation and purification of lipid cell-wall components
GB9813100D0 (en) 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
BR0103887C1 (pt) 2001-07-17 2005-11-08 Univ Minas Gerais Composições imunogênicas contendo microesferas biodegradáveis encapsulando antìgenos, vetores gênicos e adjuvantes
ES2231037B1 (es) 2003-10-31 2005-12-16 Archivel Technologies, Sl Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
EP1761662A4 (en) 2004-07-01 2010-02-03 Univ California PROTEOMICS WITH HIGH THROUGHPUT
DK1877426T3 (da) 2005-04-29 2012-05-14 Glaxosmithkline Biolog Sa Fremgangsmåde til forebyggelse eller behandling af M Tuberculosis-infektion.
WO2007022152A2 (en) 2005-08-15 2007-02-22 The Research Foundation Of State University Of New York Lipid nano particulates containing antigens as cancer vaccines
ES2564241T3 (es) 2005-12-02 2016-03-21 Glaxosmithkline Biologicals Sa Nanopartículas para su uso en composiciones inmunogénicas
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
AU2006342615B8 (en) 2006-04-20 2012-07-05 Tokai University Educational System Therapeutic agent for allergy containing liposome having oligosaccharide on its surface
EP2076244B1 (en) 2006-10-10 2016-12-07 Jina Pharmaceuticals Inc. Aqueous systems for the preparation of lipid-based pharmaceutical compounds; compositions, methods, and uses thereof
ES2307402B1 (es) 2006-10-30 2009-09-30 Archivel Farma, S.L. Vacuna profilactica contra la tuberculosis.
CN101969976A (zh) 2008-01-11 2011-02-09 美国政府健康与人类服务部秘书处 针对分枝杆菌的多肽疫苗和接种策略
ES2335177B1 (es) * 2008-09-19 2011-02-28 Archivel Farma, S.L. Agente inmunoterapeutico apropiado para la profilaxis primaria de la tuberculosis.
BRPI1006452A2 (pt) 2009-04-24 2016-12-27 Statens Seruminstitut vacina ou composição imunogênica que é administrada após a exposição a indivíduos com infecção latente que previne a reativação de tuberculose; método para tratar um animal, incluindo o ser humano, contra a reativação da infecção por tuberculose causada por micobactérias virulentas, uso de um antígeno selecionado do grupo
US9352030B2 (en) 2010-12-14 2016-05-31 Glaxosmithkline Biologicals, S.A. Mycobacterium antigenic composition

Also Published As

Publication number Publication date
RU2014133042A (ru) 2016-02-27
IN2014MN01594A (pt) 2015-05-08
DK2802345T3 (en) 2018-04-30
BR112014017217A8 (pt) 2017-07-04
BR112014017217B1 (pt) 2023-01-17
CA2861074C (en) 2018-11-06
PT2802345T (pt) 2018-04-24
CN104411326A (zh) 2015-03-11
US20150132364A1 (en) 2015-05-14
PL2802345T3 (pl) 2018-08-31
EP2802345A1 (en) 2014-11-19
AU2012365465B2 (en) 2017-05-18
NO2802345T3 (pt) 2018-08-04
ZA201405107B (en) 2020-11-25
ES2670493T3 (es) 2018-05-30
US9682042B2 (en) 2017-06-20
WO2013104943A1 (en) 2013-07-18
RU2602771C2 (ru) 2016-11-20
AU2012365465A1 (en) 2014-08-21
EP2802345B1 (en) 2018-03-07
CN104411326B (zh) 2018-02-02
CA2861074A1 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
FR21C1059I2 (fr) Compositions pharmaceutiques
HK1226301A1 (zh) 修飾的治療劑及其組合物
BR112014009634A2 (pt) preparação e agente terapêutico
HK1205690A1 (en) Pharmaceutical composition and administration thereof
BR112015002738A2 (pt) composto , e , composição farmacêutica
IL252566A0 (en) Pharmacy preparations and methods
DK3030262T3 (da) Kombineret farmaceutisk sammensætning
BR112014023937A2 (pt) composição farmacêutica, agente farmacêutico de combinação e método de tratamento
DK3181128T3 (da) Farmaceutisk nilotinib-sammensætning
DK2925788T3 (da) Sammensætninger og produkter omfattende nanocellulose
BR112015003354A8 (pt) métodos e composições de microcápsula
BR112013013311A2 (pt) agente terapêutico de indução de citotoxicidade
BR112013014644A2 (pt) composição farmacêutica e complexo
DK2897594T3 (da) Farmaceutisk sammensætning
CL2014002522A1 (es) Agente inmunomodulador y usos para el mismo
CY2200004T2 (el) Σκευασματα δαπτομυκινης και χρησεις αυτων
BR112014026357A2 (pt) composição e sistema
ZA201409508B (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
EP2995308A4 (en) ANTI-HYPOXIC PHARMACEUTICAL COMPOSITION AND USE THEREOF
HK1219691A1 (zh) 醫藥組成物及其用途
BR112013010709A2 (pt) derivado de ácido trans-2-decenoico e agente farmacêutico contendo o mesmo
BR112015002646A2 (pt) composto e composição farmacêutica
BR112015014386A2 (pt) dispositivo de distribuição de agente intramiocárdico e métodos relacionados
BR112014009501A2 (pt) organogel e com´posição cosmética
ITRE20110042A1 (it) Agente sanitario

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.21 NA RPI NO 2539 DE 03/09/2019 POR TER SIDO INDEVIDA.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/01/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2757 DE 07-11-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.